Facebook
Twitter
Telegram
Report an ErrorInVivo Therapeutics Holdings Corp. Balance Sheet 2011-2024 | NVIV
Annual Balance Sheet InVivo Therapeutics Holdings Corp.
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-15.4 M | -17.7 M | -18.7 M | -5.29 M | -16.6 M | -12.1 M | -20.2 M | -18.5 M | -11.5 M | -12 M | -11.2 M | -4.23 M |
Long Term Debt |
553 K | 949 K | 693 K | - | - | 400 K | 852 K | 1.28 M | 1.6 M | 1.94 M | 1.58 M | 83.8 K |
Long Term Debt Current |
396 K | 361 K | 327 K | 294 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | 752 K | 1.08 M | 61 K | 823 K | 987 K | 1.55 M | 1.6 M | 1.94 M | 1.58 M | 122 K |
Total Current Liabilities |
2.47 M | 2.61 M | 1.97 M | 2.66 M | 2.2 M | 3.11 M | 4.85 M | 3.31 M | 9.18 M | 2.27 M | 16.8 M | 36.7 M |
Total Liabilities |
3.08 M | 3.66 M | 2.72 M | 3.74 M | 2.27 M | 3.94 M | 5.84 M | 4.86 M | 10.8 M | 4.21 M | 18.4 M | 36.9 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-249 M | -238 M | -228 M | -219 M | -207 M | -184 M | -157 M | -134 M | -100 M | -81.9 M | -43.2 M | -47.8 M |
Total Assets |
18.8 M | 21.8 M | 21.9 M | 9.32 M | 18.4 M | 14 M | 34.8 M | 21.8 M | 16.7 M | 17.1 M | 16.1 M | 5.7 M |
Cash and Cash Equivalents |
16.4 M | 19 M | 19.5 M | 6.6 M | 16.7 M | 12.9 M | 21.5 M | 14.9 M | 13.5 M | 14 M | 12.8 M | 4.36 M |
Book Value |
15.7 M | 18.1 M | 19.2 M | 5.58 M | 16.1 M | 10.1 M | 28.9 M | 16.9 M | 5.92 M | 12.9 M | -2.31 M | -31.2 M |
Total Shareholders Equity |
15.7 M | 18.1 M | 19.2 M | 5.58 M | 16.1 M | 10.1 M | 28.9 M | 16.9 M | 5.92 M | 12.9 M | -2.31 M | -31.2 M |
All numbers in USD currency
Quarterly Balance Sheet InVivo Therapeutics Holdings Corp.
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | 280 K | 417 K | 553 K | 656 K | 755 K | 853 K | 949 K | 530 K | 629 K | 605 K | 693 K | 693 K | 693 K | 693 K | 1.02 M | 1.02 M | 1.02 M | 1.02 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
666 K | 1.76 M | 2.18 M | 3.08 M | 3.26 M | 3.26 M | 3.02 M | 3.66 M | 2.63 M | 2.5 M | 2.16 M | 2.72 M | 2.72 M | 2.72 M | 2.72 M | 3.74 M | 3.74 M | 3.74 M | 3.74 M | 2.27 M | 2.27 M | 2.27 M | 2.27 M | 3.94 M | 3.94 M | 3.94 M | 3.94 M | 5.84 M | 5.84 M | 5.84 M | 5.84 M | 4.86 M | 4.86 M | 4.86 M | 4.86 M | 10.8 M | 10.8 M | 10.8 M | 10.8 M | 4.21 M | 4.21 M | 4.21 M | 4.21 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 36.9 M | 36.9 M | 36.9 M | 36.9 M |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-256 M | -253 M | -251 M | -249 M | -246 M | -244 M | -241 M | -238 M | -235 M | -233 M | -230 M | -228 M | -228 M | -228 M | -228 M | -219 M | -219 M | -219 M | -219 M | -207 M | -207 M | -207 M | -207 M | -184 M | -184 M | -184 M | -184 M | -157 M | -157 M | -157 M | -157 M | -134 M | -134 M | -134 M | -134 M | -100 M | -100 M | -100 M | -100 M | -81.9 M | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
9.58 M | 13.3 M | 15.7 M | 18.8 M | 13.4 M | 16.1 M | 18.5 M | 21.8 M | 23.6 M | 25.8 M | 27.7 M | 21.9 M | 21.9 M | 21.9 M | 21.9 M | 9.32 M | 9.32 M | 9.32 M | 9.32 M | 18.4 M | 18.4 M | 18.4 M | 18.4 M | 14 M | 14 M | 14 M | 14 M | 34.8 M | 34.8 M | 34.8 M | 34.8 M | 21.8 M | 21.8 M | 21.8 M | 21.8 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 17.1 M | 17.1 M | 17.1 M | 17.1 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 5.7 M | 5.7 M | 5.7 M | 5.7 M |
Cash and Cash Equivalents |
8.58 M | 10.7 M | 13.1 M | 16.4 M | 10.7 M | 13.2 M | 15.3 M | 19 M | 21.3 M | 23.2 M | 24.8 M | 19.6 M | 19.5 M | 19.5 M | 19.5 M | 6.6 M | 6.6 M | 6.6 M | 6.6 M | 16.7 M | 16.7 M | 16.7 M | 16.7 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 21.5 M | 21.5 M | 21.5 M | 21.5 M | 14.9 M | 20.2 M | 20.2 M | 20.2 M | 13.5 M | 13.5 M | 13.5 M | 13.5 M | 14 M | 14 M | 14 M | 14 M | 12.8 M | 12.8 M | 12.8 M | 12.8 M | 4.36 M | 4.36 M | 4.36 M | 4.36 M |
Book Value |
8.92 M | 11.6 M | 13.5 M | 15.7 M | 10.1 M | 12.8 M | 15.5 M | 18.1 M | 20.9 M | 23.3 M | 25.5 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 5.58 M | 5.58 M | 5.58 M | 5.58 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 28.9 M | 28.9 M | 28.9 M | 28.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 5.92 M | 5.92 M | 5.92 M | 5.92 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | -2.31 M | -2.31 M | -2.31 M | -2.31 M | -31.2 M | -31.2 M | -31.2 M | -31.2 M |
Total Shareholders Equity |
8.92 M | 11.6 M | 13.5 M | 15.7 M | 10.1 M | 12.8 M | 15.5 M | 18.1 M | 20.9 M | 23.3 M | 25.5 M | 19.2 M | 19.2 M | 19.2 M | 19.2 M | 5.58 M | 5.58 M | 5.58 M | 5.58 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 10.1 M | 10.1 M | 10.1 M | 10.1 M | 28.9 M | 28.9 M | 28.9 M | 28.9 M | 16.9 M | 16.9 M | 16.9 M | 16.9 M | 5.92 M | 5.92 M | 5.92 M | 5.92 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | -2.31 M | -2.31 M | -2.31 M | -2.31 M | -31.2 M | -31.2 M | -31.2 M | -31.2 M |
All numbers in USD currency